Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Metabolism of Mosliciguat in Healthy Males
NCT07185321Phase 1Completed
- Sponsor
- Pulmovant
- Start
- Jun 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mosliciguat in pulmonary hypertension (PH) (2 arms), sponsored by Pulmovant. Primary endpoints: Absolute Bioavailability at Day 7, Area under the concentration-time curve at Day 7 and 2 more. Started Jun 2025; status: completed.
02
Drugs
mosliciguat
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07185321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185321.